Heart device effect on tricuspid valve and right heart
Part of Heart & circulation clinical trials.
This study looks at how a new pacemaker or defibrillator (CIED) might affect the tricuspid valve and the right side of the heart. It aims to understand these changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to give written permission to join the study.
- You are getting a new pacemaker or defibrillator for the first time.
- Your heart images from an echo test are clear enough to check the tricuspid valve and right heart.
- You do not have a pacemaker or defibrillator already in place.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a catheter-based procedure using the TricValve system for people with severe “tricuspid regurgitation” (a leaky tricuspid valve) who are very symptomatic. It may help reduce the backflow and improve heart function, especially for people who are too unwell for or not helped by standard options.
This study looks at how a new pacemaker or defibrillator lead may affect the tricuspid valve (the valve between the right upper and lower heart chambers). It helps doctors understand if the lead causes leakage (regurgitation) over time.
This study looks at how pacemakers and similar heart devices affect the tricuspid valve over time and whether that leads to worse health outcomes. It may help you understand if your device is causing long-term changes.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study looks at how the heart adjusts after a procedure to replace the tricuspid valve (the valve between the right upper and lower heart chambers). It focuses on patients who need medication to support their blood pressure within 24 hours after the procedure, to better understand and manage this unstable period.
This study tracks patients with weak heart pumps and leaky tricuspid valves (a valve on the right side of the heart) who receive a minimally invasive repair procedure. The goal is to understand how this treatment affects patients' heart function and quality of life over time.
Hear when a new Cardiac Pacing, Artificial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.